DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Multiple Sclerosis | Unmet Need | Primary-Progressive Multiple Sclerosis | US/EU5 | 2019
Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS), the first of its kind. According to…
Multiple Sclerosis – Unmet Need – Unmet Need – Primary-Progressive Multiple Sclerosis (US/EU)
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Adult | US | 2023
Attention-deficit / hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders that can continue into adulthood. This condition entails several recurring problems,…
Major Depressive Disorder (DSM-V) – Special Topics – Special Topics: Novel Drugs in Psychiatry (US)
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Post-Traumatic Stress Disorder – Special Topics – Special Topics: Novel Drugs in Psychiatry (US)
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Major Depressive Disorder (DSM-V) – Special Topics – Special Topics: Comorbidities in Major Depressive Disorder (US)
Psychiatric disorders such as anxiety, posttraumatic stress disorder (PTSD), and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists…
